Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 3/20 | 0.62 |
| ▸ | AGTR2 | P50052 | 3/20 | 0.62 |
| ▸ | C5AR1 | P21730 | 2/20 | 0.62 |
| ▸ | NTSR2 | O95665 | 10/20 | 0.58 |
| ▸ | NTSR1 | P30989 | 10/20 | 0.58 |
| ▸ | SORT1 | Q99523 | 10/20 | 0.58 |
| ▸ | REN | P00797 | 2/20 | 0.55 |
| ▸ | ANPEP | P15144 | 1/20 | 0.54 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.54 |
| ▸ | APLNR | P35414 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9010599 | 1.00 | AGTR1 (0.62) | AGTR1AGTR2C5AR1NTSR2NTSR1 | |
| SCHEMBL29649735 | 1.00 | AGTR1 (0.62) | AGTR1AGTR2C5AR1NTSR2NTSR1 | |
| Acetic Acid SCHEMBL29619795 | 0.99 | AGTR1 (0.61) | AGTR1AGTR2C5AR1NTSR2NTSR1 | |
| SCHEMBL29976843 | 0.97 | C5AR1 (0.58) | AGTR1AGTR2C5AR1NTSR2NTSR1 | |
| SCHEMBL8741230 | 0.97 | C5AR1 (0.59) | AGTR1AGTR2C5AR1NTSR2NTSR1 | |
| SCHEMBL29976469 | 0.97 | C5AR1 (0.65) | AGTR1AGTR2C5AR1NTSR2NTSR1 | |
| SCHEMBL29619803 | 0.97 | C5AR1 (0.65) | AGTR1AGTR2C5AR1NTSR2NTSR1 | |
| SCHEMBL29973760 | 0.96 | AGTR2 (0.63) | AGTR1AGTR2C5AR1NTSR2NTSR1 | |
| SCHEMBL29701260 | 0.96 | C5AR1 (0.60) | AGTR1AGTR2C5AR1NTSR2NTSR1 | |
| Angiotensin Ii SCHEMBL9013957 | 0.95 | AGTR2 (0.69) | AGTR1AGTR2C5AR1NTSR2NTSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090251-A1 | METHODS FOR IMPROVING TREATMENT OUTCOMES IN PATIENTS UNDERGOING ULTRAFILTRATION | PROLETARIAT THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260060962-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | CAPACITY BIO INC (US) | 2026-03-05 | — | — | US | disclosed |
| EP-4021571-B1 | THERAPY GUIDANCE AND/OR THERAPY MONITORING FOR TREATMENT OF SHOCK | 4TEEN4 Pharmaceuticals GmbH (DE) | 2025-10-08 | — | — | EP | disclosed |
| EP-4596689-A1 | ENZYME AGENT AND USE THEREOF | Amano Enzyme Inc. (JP) | 2025-08-06 | — | — | EP | disclosed |
| US-12343331-B2 | Methods and agents that stimulate mitochondrial turnover for treating disease | Capacity Bio, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20250206779-A1 | ANGIOTENSIN-(1-9) ANALOGUE BASED ON D AMINO ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | UNIVERSIDAD DE CHILE (CL) | 2025-06-26 | — | — | US | disclosed |
| CN-120092086-A | Enzyme agent and application thereof | 天野酶制品株式会社 | 2025-06-03 | — | — | CN | disclosed |
| EP-4552649-A2 | THERAPY GUIDANCE AND/OR THERAPY MONITORING FOR TREATMENT OF SHOCK | 4TEEN4 Pharmaceuticals GmbH (DE) | 2025-05-14 | — | — | EP | disclosed |
| WO-2024143729-A1 | COMPOSITION COMPRISING ANGIOTENSIN III FOR REDUCING METHANE PRODUCTION OF RUMINANTS | 대한민국(농촌진흥청장) | 2024-07-04 | — | — | WO | disclosed |
| WO-2024071388-A1 | ENZYME AGENT AND USE THEREOF | 天野エンザイム株式会社 | 2024-04-04 | — | — | WO | disclosed |
| US-11583568-B2 | Methods for administering angiotensin II | LA JOLLA PHARMA, LLC (US) | 2023-02-21 | — | — | US | disclosed |
| EP-4067370-A1 | HIGH PENETRATION PRODRUG COMPOSITIONS OF PEPTIDES AND PEPTIDE RELATED COMPOUNDS | Yu, Chongxi (US) | 2022-10-05 | — | — | EP | disclosed |
| US-20220307065-A1 | THERAPY GUIDANCE AND/OR THERAPY MONITORING FOR TREATMENT OF SHOCK | 4TEEN4 Pharmaceuticals GmbH (DE) | 2022-09-29 | — | — | US | disclosed |
| US-20220288164-A1 | METHOD TO INCREASE SYSTEMIC BLOOD PRESSURE IN SHOCK | GEORGETOWN UNIVERSITY | 2022-09-15 | — | — | US | disclosed |
| US-20220233507-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | Capacity Bio, Inc. | 2022-07-28 | — | — | US | disclosed |
| US-20220211798-A1 | THERAPY GUIDANCE AND/OR THERAPY MONITORING FOR A TREATMENT WITH ANGIOTENSIN-RECEPTOR-AGONIST AND/OR A PRECURSOR THEREOF | 4TEEN4 Pharmaceuticals GmbH (DE) | 2022-07-07 | — | — | US | disclosed |
| EP-4021571-A1 | THERAPY GUIDANCE AND/OR THERAPY MONITORING FOR TREATMENT OF SHOCK | 4TEEN4 Pharmaceuticals GmbH (DE) | 2022-07-06 | — | — | EP | disclosed |
| CN-114556100-A | Therapy guidance and/or therapy monitoring for treatment of shock | 4TEEN4制药有限公司 | 2022-05-27 | — | — | CN | disclosed |
| EP-0740790-A1 | HOMOGENEOUS IMMUNOASSAYS AND ENZYME BASED ASSAYS OF ANALYTES USING CAPILLARY ELECTROPHORESIS | BECKMAN INSTRUMENTS, INC. (US) | 1996-11-06 | — | — | EP | disclosed |
| WO-1995020161-A1 | HOMOGENEOUS IMMUNOASSAYS AND ENZYME BASED ASSAYS OF ANALYTES USING CAPILLARY ELECTROPHORESIS | BECKMAN INSTRUMENTS, INC. (US) | 1995-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220288164-A1 | METHOD TO INCREASE SYSTEMIC BLOOD PRESSURE IN SHOCK | VASP, TRPV1, BDKRB2 | AGTR1 236/4885AGTR2 203/4885C5AR1 990/4885 |
| US-12343331-B2 | Methods and agents that stimulate mitochondrial turnover for treating disease | NLN, MAVS, PINK1 | AGTR1 242/4885AGTR2 337/4885C5AR1 939/4885 |
| US-20220233507-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | NLN, MAVS, PINK1 | AGTR1 242/4885AGTR2 337/4885C5AR1 939/4885 |
| US-20260060962-A1 | METHODS AND AGENTS THAT STIMULATE MITOCHONDRIAL TURNOVER FOR TREATING DISEASE | MDH2, NLN, PINK1 | AGTR1 1006/4885AGTR2 1203/4885C5AR1 3824/4885 |
| US-20220211798-A1 | THERAPY GUIDANCE AND/OR THERAPY MONITORING FOR A TREATMENT WITH ANGIOTENSIN-RECEPTOR-AGONIST AND/OR A PRECURSOR THEREOF | DPP3, ACE, FABP3 | AGTR1 5/4885AGTR2 9/4885C5AR1 116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.